Makary names Vinay Prasad CBER chief; Q1 earn­ings re­port; More on “Most Fa­vored Na­tions"; and more

Yesterday
Weekly

Chron­ic care start­up Oma­da Health files to go pub­lic

2 days ago
Financing
Startups

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

2 days ago
Pharma
Manufacturing

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

2 days ago
News Briefing

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

2 days ago
R&D

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

2 days ago
Pharma
Manufacturing

In­tro­duc­ing the new End­points pro­file ex­pe­ri­ence

2 days ago
Publisher's note

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

2 days ago
Peer Review

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

2 days ago
R&D

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

2 days ago
Financing
Startups

Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal

3 days ago
Pharma
Diagnostics

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

3 days ago
Pharma

Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales

3 days ago
Pharma
Diagnostics

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

3 days ago
People
AI

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

3 days ago
Pharma
Law

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

3 days ago
Pharma
FDA+

FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment

3 days ago
Pharma
FDA+

Bris­tol My­er­s' $40B US in­vest­ment; Sh­iono­gi to buy Japan­ese drug­mak­er

3 days ago
Manufacturing

ALX On­col­o­gy won’t seek ap­proval for CD47 drug in gas­tric can­cer; Ko­r­ro Bio’s lay­offs

3 days ago
News Briefing

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

3 days ago
People

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

3 days ago
R&D
Cell/Gene Tx

HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact

3 days ago
Financing
Startups

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

3 days ago
R&D

FDA will con­vene vac­cine ad­vi­sors to dis­cuss Covid strain up­dates

4 days ago
Pharma
FDA+
1234 Next page Last page
A service from the Financial Times